Series A · Biotech · Copenhagen, Denmark · Founded 2020
Muna Therapeutics develops first-in-class small molecule therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, and Frontotemporal Dementia. Founded in 2020 by leading researchers from Aarhus University and VIB-KU Leuven, the company focuses on repairing neuronal dysfunction and resolving neuroinflammation. The startup raised $73 million in Series A funding in July 2021, co-led by Novo Holdings, Sofinnova Partners, Droia Ventures, and LSP Dementia Fund. Their innovative drug discovery platform leverages spatial transcriptomics, AI-driven computational chemistry, and proprietary insights into molecular pathways that confer brain cell resilience to disease pathology.
No open roles listed right now.